ArticleMolecular and cellular therapies2014
Therapeutic Opportunities for Targeting microRNAs in Cancer.
Article in Molecular and cellular therapies, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Effect of microRNA-141-3p, E2F3, CDK3, and KAT2B overexpression on histologic tumor grade and metastasis status in untreated breast cancer tissues.BioImpacts : BI · 2025Article
- Article
- Synergistic Effects of A Combined Treatment of Glioblastoma U251 Cells with An Anti-miR-10b-5p Molecule and An AntiCancer Agent Based on 1-(3',4',5'-Trimethoxyphenyl)-2-Aryl-1International journal of molecular sciences · 2022Article
- Treatment of Human Glioblastoma U251 Cells with Sulforaphane and a Peptide Nucleic Acid (PNA) Targeting miR-15b-5p: Synergistic Effects on Induction of Apoptosis.Molecules (Basel, Switzerland) · 2022Article
- Synergistic effects of the combined treatment of U251 and T98G glioma cells with an anti‑tubulin tetrahydrothieno[2,3‑c]pyridine derivative and a peptide nucleic acid targeting miR‑221‑3p.International journal of oncology · 2021Article
- A Distinctive microRNA (miRNA) Signature in the Blood of Colorectal Cancer (CRC) Patients at Surgery.Cancers · 2020Article
- Serum miRNAs, a potential prognosis marker of loco-regionally advanced nasopharyngeal carcinoma patients treated with CCRT.BMC cancer · 2020Article
- MicroRNA-183 in Cancer Progression.Journal of Cancer · 2020Review
- Targeting miR‑155‑5p and miR‑221‑3p by peptide nucleic acids induces caspase‑3 activation and apoptosis in temozolomide‑resistant T98G glioma cells.International journal of oncology · 2019Article
- Article
- G-Quadruplexes influence pri-microRNA processing.RNA biology · 2018Article
- SASP regulation by noncoding RNA.Mechanisms of ageing and development · 2017Review
- 3' UTR G-quadruplexes regulate miRNA binding.RNA (New York, N.Y.) · 2017Article
- Article
- Functional Roles for Exosomal MicroRNAs in the Tumour Microenvironment.Computational and structural biotechnology journal · 2017Review
- Article
- MicroRNA-150 Suppression of Angiopoetin-2 Generation and Signaling Is Crucial for Resolving Vascular Injury.Arteriosclerosis, thrombosis, and vascular biology · 2016Article
- Epigenetic control of phospholipase A2 receptor expression in mammary cancer cells.BMC cancer · 2015Article
- Circulating MicroRNAs as Biomarkers and Mediators of Cell-Cell Communication in Cancer.Biomedicines · 2015Review
- The increasing need for biomarkers in intensive care unit-acquired weakness--are microRNAs the solution?Critical care (London, England) · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
MicroRNAs (miRNAs) are small noncoding RNAs that can function as either powerful tumor promoters or suppressors in numerous types of cancer. The ability of miRs to target multiple genes and biological signaling pathways has created intense interest in their potential clinical utility as predictive and diagnostic biomarkers, and as innovative therapeutic agents. Recently, accumulating preclinical studies have illustrated the feasibility of slowing tumor progression by either overexpressing tumor suppressive miRNAs, or by neutralizing the activities of oncogenic miRNAs in cell- and animal-based models of cancer. Here we highlight prominent miRNAs that may represent potential therapeutic targets in human malignancies, as well as review current technologies available for inactivating or restoring miRNA activity in clinical settings.
Indexed as
Identifiers
25717380PMC4337831What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.